Phase II study of recombinant human interleukin 3 administration following carboplatin and etoposide chemotherapy in small-cell lung cancer patients. SDZ ILE 964 (IL-3) Study.

S Kudoh; T Sawa; N Kurihara; K Furuse; Y Kurita; M Fukuoka; M Takada; F Takaku; M Ogawa; Y Ariyoshi

doi:10.1007/s002800051046

Phase II study of recombinant human interleukin 3 administration following carboplatin and etoposide chemotherapy in small-cell lung cancer patients. SDZ ILE 964 (IL-3) Study.

Identifier:nobleid.org/w1/20260515/BC9B0F9E

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/BC9B0F9E.svg?ark=w1%2F20260515%2FBC9B0F9E)](https://nobleid.org/work/w1/20260515/BC9B0F9E)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Phase II study of recombinant human interleukin 3 administration following carboplatin and etoposide chemotherapy in small-cell lung cancer patients. SDZ ILE 964 (IL-3) Study.

Identifier:nobleid.org/w1/20260515/BC9B0F9E

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/BC9B0F9E.svg?ark=w1%2F20260515%2FBC9B0F9E)](https://nobleid.org/work/w1/20260515/BC9B0F9E)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work